Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2018 to Q4 2025

Type / Class
Equity / Class A Common Stock, par value $0.01
Symbol
AMRX on Nasdaq
Shares outstanding
315,976,000
Price per share
$13.26
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
154,415,487
Total reported value
$1,945,382,380
% of total 13F portfolios
0%
Share change
+3,371,747
Value change
+$48,171,839
Number of holders
271
Price from insider filings
$13.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Patel Tushar Bhikhubhai 16% $363,365,003 48,578,209 Patel Tushar Bhikhubhai 14 Mar 2025
Patel Chintu 8.2% $259,359,420 25,910,032 Patel Chintu 03 Oct 2025
Patel Dipan 7.6% -1.2% $238,528,210 23,828,992 0% Patel Dipan 03 Oct 2025
Patel Chirag K. 7.1% $179,439,606 22,180,421 Patel Chirag K. 06 Aug 2025
Mahesh Akram 6.6% $153,779,517 20,558,759 Akram Mahesh 31 Mar 2025
VANGUARD GROUP INC 5% $117,905,198 15,762,727 The Vanguard Group 31 Mar 2025

As of 31 Dec 2025, 271 institutional investors reported holding 154,415,487 shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX). This represents 49% of the company’s total 315,976,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) together control 37% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 5.7% 17,907,815 -0.26% 0% $225,638,469
BlackRock, Inc. 4.5% 14,298,520 +1.6% 0% $180,161,353
Rubric Capital Management LP 3.9% 12,334,941 0% 1.9% $155,420,257
TPG GP A, LLC 3.9% 12,328,767 0% 5.8% $155,342,464
CITADEL ADVISORS LLC 2% 6,175,737 +7.8% 0.05% $77,814,286
DIMENSIONAL FUND ADVISORS LP 1.8% 5,609,040 +3.3% 0.01% $70,680,550
MORGAN STANLEY 1.5% 4,818,099 +38% 0% $60,708,057
STATE STREET CORP 1.3% 4,110,410 +3.4% 0% $51,791,166
GEODE CAPITAL MANAGEMENT, LLC 1.3% 3,986,554 -1.2% 0% $50,239,137
Assenagon Asset Management S.A. 1.2% 3,761,739 +75% 0.07% $47,397,911
NEUBERGER BERMAN GROUP LLC 1.2% 3,655,391 -1.6% 0.03% $46,098,068
MILLENNIUM MANAGEMENT LLC 1.1% 3,360,198 +0.82% 0.03% $42,338,495
Nuveen, LLC 1% 3,221,721 -0.11% 0.01% $40,593,684
D. E. Shaw & Co., Inc. 0.84% 2,661,854 +70% 0.03% $33,539,360
GOLDMAN SACHS GROUP INC 0.82% 2,581,075 +4.9% 0% $32,521,545
Nantahala Capital Management, LLC 0.77% 2,447,516 -42% 1.8% $30,838,702
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.68% 2,144,471 +3% 0% $27,020,329
ACADIAN ASSET MANAGEMENT LLC 0.64% 2,021,171 -22% 0.04% $25,455,000
Invesco Ltd. 0.55% 1,750,718 +3.9% 0% $22,059,048
BlackBarn Capital Partners LP 0.5% 1,570,000 -28% 7.1% $19,782,000
NORTHERN TRUST CORP 0.49% 1,546,347 -5% 0% $19,483,972
Allspring Global Investments Holdings, LLC 0.47% 1,480,172 +30% 0.03% $18,738,978
PFM Health Sciences, LP 0.46% 1,465,480 +312% 1.9% $18,465,048
Westshore Wealth, LLC 0.44% 1,381,910 0% 5.8% $17,412,066
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.42% 1,326,540 +3.7% 0.02% $16,714,404

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 154,415,487 $1,945,382,380 +$48,171,839 $12.60 271
2025 Q3 150,649,016 $1,508,360,946 +$80,604,600 $10.01 244
2025 Q2 141,656,835 $1,146,033,099 +$54,531,142 $8.09 237
2025 Q1 134,631,456 $1,128,246,067 +$84,513,755 $8.38 232
2024 Q4 125,924,024 $997,296,789 -$136,424,861 $7.92 194
2024 Q3 142,604,811 $1,186,537,394 +$32,304,784 $8.32 180
2024 Q2 138,637,695 $880,361,225 +$192,128,358 $6.35 179
2024 Q1 108,100,411 $655,086,509 -$6,545,489 $6.06 173
2023 Q4 109,241,884 $663,112,026 +$52,701,039 $6.07 151
2023 Q3 101,896,343 $430,042,448 +$19,693,333 $4.22 141
2023 Q2 97,368,877 $301,754,419 +$4,221,215 $3.10 122
2023 Q1 96,883,833 $134,657,443 -$8,205,387 $1.39 142
2022 Q4 101,876,885 $202,739,453 +$4,463,674 $1.99 155
2022 Q3 99,522,767 $201,053,119 -$1,681,376 $2.02 144
2022 Q2 99,362,374 $315,991,849 -$2,095,558 $3.18 140
2022 Q1 100,125,536 $417,146,539 -$2,779,055 $4.17 154
2021 Q4 100,743,592 $481,044,810 -$750,941 $4.79 148
2021 Q3 100,372,906 $535,260,080 +$2,515,423 $5.34 150
2021 Q2 99,933,342 $511,565,477 -$13,076,955 $5.12 153
2021 Q1 101,580,612 $683,525,934 +$24,752,974 $6.73 155
2020 Q4 99,489,363 $454,601,386 -$9,010,325 $4.57 128
2020 Q3 101,459,246 $393,634,017 -$1,370,007 $3.88 133
2020 Q2 101,691,059 $484,034,077 +$16,566,905 $4.76 131
2020 Q1 98,300,162 $342,039,040 -$17,271,636 $3.48 117
2019 Q4 101,152,211 $487,526,241 -$9,606,036 $4.82 116
2019 Q3 108,293,336 $314,077,694 -$45,957,076 $2.90 111
2019 Q2 105,380,317 $755,561,286 -$88,067,679 $7.17 116
2019 Q1 109,021,244 $1,544,805,998 -$98,023,386 $14.17 150
2018 Q4 116,187,735 $1,572,087,804 +$89,696,977 $13.53 157
2018 Q3 108,476,937 $2,407,193,089 +$282,716,887 $22.19 162
2018 Q2 97,469,656 $1,599,487,071 +$1,599,409,043 $16.41 163